As expected, we confirmed that low-grade SSTR2 expression (i.e., score 0–1 vs. 2–3) was significantly more frequent among resistant adenomas (40.9 vs. 14.3%, R-SRL vs. S-SRL, p = 0.024) (Table 5). The gene discussed is SSTR2; the disease is adenoma.